The Priority Review

Tag

HMPL-306

1 story

  1. Clinical trials

    Hutchmed registers Phase III trial of HMPL-306 in postoperative residual or recurrent grade 2 glioma

    The study plans to enroll 210 participants and plans to begin in November 2026, with primary completion projected for March 2032. It is a randomized, double-blind, placebo-controlled multicenter Phase III trial evaluating HMPL-306 tablet safety and efficacy.